Arrowhead Pharmaceuticals Reports Fiscal 2023 Second Quarter Results
- Conference Call and Webcast Today, May 2, 2023 at 4:30 p.m. ET
Webcast and Conference Call and Details
Investors may access a live audio webcast on the Company's website at http://ir.arrowheadpharma.com/events.cfm. A replay of the webcast will be available approximately two hours after the conclusion of the call.
For analysts that wish to participate in the conference call, please register at https://register.vevent.com/register/BIf9cd65655e5444119df91cd4891157f8. Once registered, you will receive the dial-in number and a personalized PIN code that will be required to access the call.
Selected Recent Events
-
Reported interim results from an ongoing Phase 1/2 clinical study of ARO-RAGE, an investigational RNAi therapeutic for treatment for inflammatory pulmonary diseases, such as asthma. These data represent the first clinical demonstration of the potential utility of Arrowhead’s proprietary Targeted RNAi Molecule (TRiMTM) platform optimized for delivery to the lungs. Key results from Part 1 of the study in normal healthy volunteers included the following:
-
Mean maximum reduction in soluble RAGE (sRAGE) as measured in serum after two doses of 92 mg on Day 1 and Day 29 was
80% with a maximum reduction of90% - Duration of pharmacologic effect persisted for at least 6 weeks
-
Mean reduction in sRAGE as measured in bronchoalveolar lavage fluid (BALF) at Day 31 after a single dose of 92 mg was
75% with a maximum reduction of92% -
Mean maximum reduction of
56% with a maximum reduction of68% in serum sRAGE was also observed after a single dose of 92 mg -
Safety and tolerability
- Overall, no patterns of adverse changes in any clinical safety parameters
- No reported serious or severe adverse events
- No dropouts related to drug or related to adverse events
- These results include 4 of 5 escalating dose levels. Data are not yet available for single or multiple dose cohorts at 184 mg, the highest dose being tested
-
Mean maximum reduction in soluble RAGE (sRAGE) as measured in serum after two doses of 92 mg on Day 1 and Day 29 was
-
Announced a planned R&D Day on June 1, 2023, which will include presentations on cardiometabolic, pulmonary, and newly announced central nervous system (CNS) pipeline programs
- The company expanded its TRiMTM platform to include an optimized intrathecal administration for CNS delivery with good distribution throughout the brain and in all relevant brain cell types. The first development candidate to utilize this new delivery platform, ARO-SOD1, is on track for a clinical trial application filing in the third quarter of 2023 to begin clinical studies
-
In preclinical studies, ARO-SOD1 achieved
95% spinal cord tissue mRNA knockdown after a single intrathecal dose in human SOD1 transgenic rats and maintained greater than80% spinal cord tissue mRNA knockdown three months after a single intrathecal dose in non-human primates
-
Earned a
$40 million -
Received Fast Track designation from the
U.S. Food and Drug Administration (FDA) for ARO-APOC3 for reducing triglycerides in adult patients with familial chylomicronemia syndrome -
Earned a
$30 million - Initiated dosing in a Phase 1/2a single ascending dose and multiple ascending dose clinical study of ARO-MMP7, Arrowhead’s third pulmonary targeted investigational RNAi therapeutic being developed as a potential treatment for idiopathic pulmonary fibrosis
-
Reported interim results from an ongoing Phase 1/2 clinical study of ARO-C3, an investigational RNAi therapeutic for treatment of various complement mediated diseases, demonstrating mean reductions of
88% in C3 and91% in AH50, a marker of alternative complement pathway hemolytic activity - Regained rights to ARO-PNPLA3, formerly called JNJ-75220795, which was part of a 2018 research collaboration and option agreement between Arrowhead and Janssen Pharmaceuticals, Inc. ARO-PNPLA3 is an investigational RNAi therapeutic developed using Arrowhead’s proprietary TRiMTM platform and designed to reduce liver expression of patatin-like phospholipase domain containing 3 (PNPLA3) as a potential treatment for patients with NASH
-
Announced topline results with Takeda from the Phase 2 SEQUOIA clinical study of investigational fazirsiran for the treatment of AATD-LD and provided an outline of a Phase 3 study that was co-developed by Takeda and Arrowhead and will be conducted by Takeda. Key results from SEQUOIA included the following:
-
Fibrosis regression observed in
50% of patients receiving fazirsiran -
Median reductions of
94% of Z-AAT accumulation in the liver and mean reduction of68% in histologic globule burden - Treatment emergent adverse events were generally well balanced between fazirsiran and placebo groups
- Results consistent with AROAAT-2002 open-label study previously published in The New England Journal of Medicine
-
Fibrosis regression observed in
Selected Fiscal 2023 Second Quarter Financial Results |
|||||||
Three Months Ended March 31, |
|||||||
OPERATING SUMMARY |
|
2023 |
|
|
2022 |
||
|
(unaudited) |
||||||
Revenue |
$ |
146,267 |
|
$ |
151,805 |
||
Operating Expenses: |
|
|
|
||||
Research and development |
|
74,881 |
|
|
75,985 |
||
General and administrative expenses |
|
23,221 |
|
|
|
34,267 |
|
Total Operating Expenses |
|
98,102 |
|
|
110,252 |
||
Operating income |
|
48,165 |
|
|
|
41,553 |
|
Interest income |
|
4,560 |
|
|
|
1,054 |
|
Interest expense |
|
(5,067 |
) |
|
|
- |
|
Other, net |
|
8 |
|
|
1,759 |
|
|
Income before income tax expense and noncontrolling interest |
|
47,676 |
|
|
|
44,366 |
|
Income tax expense |
|
- |
|
|
|
- |
|
Net income before noncontrolling interest |
|
47,676 |
|
|
|
44,366 |
|
Net loss attributable to noncontrolling interest, net of tax |
|
(999 |
) |
|
- |
||
Net income attributable to Arrowhead Pharmaceuticals, Inc. |
$ |
48,675 |
|
|
$ |
44,366 |
|
Net income per share attributable to Arrowhead Pharmaceuticals, Inc. - Diluted |
$ |
0.45 |
|
|
$ |
0.41 |
|
Weighted-average shares used in calculating - Diluted |
|
108,143 |
|
|
107,929 |
||
FINANCIAL POSITION SUMMARY |
March 31,
|
|
September 30,
|
||||
|
(unaudited) |
||||||
Cash, cash equivalents and restricted cash |
$ |
134,959 |
|
$ |
108,005 |
||
Short-term investments |
|
346,046 |
|
|
|
268,391 |
|
Long-term investments |
|
78,834 |
|
|
105,872 |
||
Total cash resources (cash and investments) |
|
559,839 |
|
|
|
482,268 |
|
Other assets |
|
331,469 |
|
|
209,671 |
||
Total Assets |
$ |
891,308 |
|
|
$ |
691,939 |
|
Current deferred revenue |
$ |
29,839 |
|
|
$ |
74,099 |
|
Long-term deferred revenue |
|
1,075 |
|
|
55,950 |
||
Other liabilities |
|
395,288 |
|
|
|
143,551 |
|
Total Liabilities |
$ |
426,202 |
|
$ |
273,600 |
||
|
|
|
|
||||
Total Arrowhead Pharmaceuticals, Inc. Stockholders' Equity |
$ |
446,772 |
|
$ |
398,520 |
||
Noncontrolling Interest |
|
18,334 |
|
|
|
19,819 |
|
Total Noncontrolling Interest and Stockholders' Equity |
|
465,106 |
|
|
418,339 |
||
Total Liabilities, Noncontrolling Interest and Stockholders' Equity |
$ |
891,308 |
|
|
$ |
691,939 |
|
Shares Outstanding |
|
106,869 |
|
|
|
105,960 |
|
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.
For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts.
Safe Harbor Statement under the Private Securities Litigation Reform Act:
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this release except for historical information may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “may,” “will,” “expect,” “believe,” “anticipate,” “hope,” “intend,” “plan,” “project,” “could,” “estimate,” “continue,” “target,” “forecast” or “continue” or the negative of these words or other variations thereof or comparable terminology are intended to identify such forward-looking statements. In addition, any statements that refer to projections of our future financial performance, trends in our business, expectations for our product pipeline or product candidates, including anticipated regulatory submissions and clinical program results, prospects or benefits of our collaborations with other companies, or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements include, but are not limited to, statements about the initiation, timing, progress and results of our preclinical studies and clinical trials, and our research and development programs; our expectations regarding the potential benefits of the partnership, licensing and/or collaboration arrangements and other strategic arrangements and transactions we have entered into or may enter into in the future; our beliefs and expectations regarding milestone, royalty or other payments that could be due to or from third parties under existing agreements; and our estimates regarding future revenues, research and development expenses, capital requirements and payments to third parties. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of numerous factors and uncertainties, including the impact of the ongoing COVID-19 pandemic on our business, the safety and efficacy of our product candidates, decisions of regulatory authorities and the timing thereof, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, the enforcement of our intellectual property rights, and the other risks and uncertainties described in our most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other documents filed with the Securities and Exchange Commission from time to time. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.
Source: Arrowhead Pharmaceuticals, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230502006103/en/
Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
626-304-3400
ir@arrowheadpharma.com
Investors:
LifeSci Advisors, LLC
Brian Ritchie
212-915-2578
britchie@lifesciadvisors.com
www.lifesciadvisors.com
Media:
LifeSci Communications, LLC
Jason Braco, Ph.D.
646-751-4361
jbraco@lifescicomms.com
www.lifescicommunications.com
Source: Arrowhead Pharmaceuticals, Inc.
